Published in Cancer Res on January 15, 1996
Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol (1997) 2.41
Both V(D)J recombination and radioresistance require DNA-PK kinase activity, though minimal levels suffice for V(D)J recombination. Nucleic Acids Res (2000) 1.65
p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc Natl Acad Sci U S A (2001) 1.55
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist (2013) 1.20
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res (2001) 1.17
The influence of DNA double-strand break structure on end-joining in human cells. Nucleic Acids Res (2001) 1.09
UV sensitivity and impaired nucleotide excision repair in DNA-dependent protein kinase mutant cells. Nucleic Acids Res (1998) 1.09
Vanillins--a novel family of DNA-PK inhibitors. Nucleic Acids Res (2003) 1.06
DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. Oncotarget (2011) 1.01
Expression of Ku70 correlates with survival in carcinoma of the cervix. Br J Cancer (2000) 0.98
HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res (2007) 0.96
Targeting the Checkpoint to Kill Cancer Cells. Biomolecules (2015) 0.94
Positive regulation of DNA double strand break repair activity during differentiation of long life span cells: the example of adipogenesis. PLoS One (2008) 0.93
Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. J Cancer Res Clin Oncol (2003) 0.93
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol (2013) 0.93
Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncol (2013) 0.93
DNA damage regulates the mobility of Brca2 within the nucleoplasm of living cells. Proc Natl Acad Sci U S A (2010) 0.91
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. Biomolecules (2015) 0.88
Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death Dis (2013) 0.87
The effect of DNA-dependent protein kinase on adeno-associated virus replication. PLoS One (2010) 0.86
Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles. ACS Nano (2015) 0.81
Wortmannin induces MCF-7 breast cancer cell death via the apoptotic pathway, involving chromatin condensation, generation of reactive oxygen species, and membrane blebbing. Breast Cancer (Dove Med Press) (2012) 0.81
Effects of the protein kinase inhibitors wortmannin and KN62 on cellular radiosensitivity and radiation-activated S phase and G1/S checkpoints in normal human fibroblasts. Br J Cancer (1999) 0.77
Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst (2014) 0.76
HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells. Neoplasia (1999) 0.75
Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res (1997) 1.62
Cdk2 kinase phosphorylates serine 315 of human p53 in vitro. Oncogene (1995) 0.95